Insights

Gathering insights about TREVI…

Similar companies to TREVI

TREVI Tech Stack

TREVI uses 8 technology products and services including jsDelivr, Open Graph, MySQL, and more. Explore TREVI's tech stack below.

jsDelivr
Content Delivery Network
Open Graph
Content Management System
MySQL
Database
DreamWeaver
Editors
Google Fonts API
Font Scripts
DataTables
Javascript Libraries
Google Search Console
Web Analytics
Gravity Forms
Web Platform Extensions

Media & News

Trevi Therapeutics Announces Upcoming June and July Event Schedule
NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July.
Jun 17, 2026 | www.globenewswire.com
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
Jun 03, 2026 | www.fool.com
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
May 12, 2026 | seekingalpha.com
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
Trevi Therapeutics NASDAQ: TRVI outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent financing.
May 09, 2026 | www.marketbeat.com
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
May 06, 2026 | seekingalpha.com
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline advancement Clinical development plans remain on track across all chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. ET  NEW HAVEN, Conn.
May 05, 2026 | www.globenewswire.com
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough count and background anti-fibrotic use An exploratory post-hoc analysis of the effects of nalbuphine ER and placebo on cough bouts from the Phase 2b CORAL trial in patients with IPF-related chronic cough and the Phase 2a RIVER trial in patients with refractory chronic cough Drug–drug interaction data from a Phase 1 study evaluating pharmacokinetics and safety following co-administration of nalbuphine ER with pirfenidone or nintedanib NEW HAVEN, Conn., April 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it will deliver an oral presentation and present multiple abstracts at the American Thoracic Society (ATS) 2026 International Conference, taking place from May 15 – 20, 2026, in Orlando, Florida.
Apr 30, 2026 | www.globenewswire.com

TREVI's Email Address Formats

TREVI uses at least 1 format(s):

TREVI Email Formats	Example	Percentage
FLast@trevi.be	JDoe@trevi.be	96%
FMiddleLast@trevi.be	JMichaelDoe@trevi.be	4%

Frequently Asked Questions

Where is TREVI's headquarters located?

TREVI's main headquarters is located at 200 Avenue Louise Ixelles, Brussels 1050 Belgium. The company has employees across 5 continents, including EuropeAsiaNorth America.

What is TREVI's stock symbol?

TREVI is a publicly traded company; the company's stock symbol is TRVI.

What is TREVI's official website and social media links?

TREVI's official website is trevi.be and has social profiles on LinkedIn.

What is TREVI's NAICS code?

TREVI's NAICS code is 531 - Real Estate.

How many employees does TREVI have currently?

As of June 2026, TREVI has approximately 116 employees across 5 continents, including EuropeAsiaNorth America. Key team members include Ceo Trevi Group: G. P.Owner: R. L.Director Trevi Nord: B. S.. Explore TREVI's employee directory with LeadIQ.

What industry does TREVI belong to?

TREVI operates in the Real Estate industry.

What technology does TREVI use?

TREVI's tech stack includes jsDelivrOpen GraphMySQLDreamWeaverGoogle Fonts APIDataTablesGoogle Search ConsoleGravity Forms.

What is TREVI's email format?

TREVI's email format typically follows the pattern of FLast@trevi.be. Find more TREVI email formats with LeadIQ.

When was TREVI founded?

TREVI was founded in 1980.

TREVI

Q: What is TREVI's official website and social media links?

TREVI's official website is trevi.be. TREVI has social profiles on LinkedIn.

Q: How many employees does TREVI have currently?

TREVI has approximately 116 employees.

Q: What technology does TREVI use?

TREVI's tech stack includes Font Awesome, Shopify, TrackJS, Gravity Forms, JSON-LD.

Q: What is TREVI's NAICS code?

TREVI's NAICS code is 531 (Real Estate).

Real EstateBrussels, Belgium51-200 Employees

TREVI is an integrated Belgian real estate group with a nationwide footprint through 38 agencies. It brings together internal offices and the Quares brand for commercial real estate and the Honesty brand for residential property, complemented by a network of TREVI Partners franchised agencies to strengthen local proximity. The group offers a comprehensive range of services, spanning residential sales and rentals, new-development projects, investment activities, viager transactions, and property management.

Based in Brussels, in the Brussels-Capital Region, TREVI has operated for more than four decades, serving individuals, investors, and businesses in valuing, managing, and transferring real estate assets. Its integrated structure supports a strategic view of the market and enables action at a national level, while providing tailored support grounded in rigor and trust.